← back to search

Jason E. Stout

Duke University · US
Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include Tuberculosis Research and Epidemiology, Mycobacterium research and diagnosis, Infectious Diseases and Tuberculosis, and Pneumocystis jirovecii pneumonia detection and treatment.
h-index
48
citations
9,795
works
231
NIH funding
primary concept
Medicine
email

Recent publications

Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases
The Lancet Infectious Diseases 2022cited by 158position: middledoi
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Nature Communications 2021cited by 292position: middledoi
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline
European Respiratory Journal 2020cited by 875position: middledoi
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline
Clinical Infectious Diseases 2020cited by 828position: middledoi
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline
Clinical Infectious Diseases 2020cited by 758position: middledoi
Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease
Clinical Infectious Diseases 2020cited by 48position: middledoi
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
New England Journal of Medicine 2019cited by 22position: firstdoi
Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement
European Respiratory Journal 2018cited by 259position: middledoi
Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma Formation and Promotes Infection
Immunity 2016cited by 243position: middledoi
Infection-Induced Vascular Permeability Aids Mycobacterial Growth
The Journal of Infectious Diseases 2016cited by 54position: middledoi
Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial
American Journal of Respiratory and Critical Care Medicine 2014cited by 112position: middledoi
Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium
The Journal of Infectious Diseases 2012cited by 110position: middledoi
Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study
BMC Public Health 2012cited by 56position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Philip Leitman · Virginia Tech5 papers (2018–2022)Enrico Tortoli · San Raffaele University of Rome5 papers (2018–2022)Lorenzo Guglielmetti · Ospedale Sacro Cuore Don Calabria5 papers (2018–2022)Erik C. Böttger · University of Zurich5 papers (2018–2022)Miguel Santín · Instituto de Salud Carlos III5 papers (2018–2022)Charles L. Daley · National Jewish Health5 papers (2018–2022)Christoph Lange · Médecins Sans Frontières5 papers (2018–2022)David E. Griffith · National Jewish Health5 papers (2018–2022)Richard J. Wallace · The University of Texas at Tyler5 papers (2018–2022)Emmanuelle Cambau · CNR de la Résistance aux Antibiotiques5 papers (2018–2022)Kenneth N. Olivier · University of North Carolina at Chapel Hill5 papers (2018–2022)Kevin Winthrop · Ohio University5 papers (2018–2022)Jakko van Ingen · Radboud University Nijmegen5 papers (2018–2022)Dirk Wagner · University Hospital Ulm5 papers (2018–2022)Shandra L. Knight · University of Colorado Denver4 papers (2020–2022)C. Andréjak · Johns Hopkins Medicine4 papers (2018–2020)Theodore K. Marras · University Health Network4 papers (2020–2022)Gwen A. Huitt · University of Colorado Denver4 papers (2018–2020)Jonathan M. Iaccarino · Università Cattolica del Sacro Cuore3 papers (2020–2020)Jan Brożek · Cochrane3 papers (2020–2020)